What are potential markers for evaluating therapeutic efficacy and prognosis in children with aplastic anemia?

Updated: Jan 29, 2021
  • Author: Sameer Bakhshi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

In a study of pediatric patients with very severe aplastic anemia, Fang et al found that the percentage of CD20+ B-cells in peripheral blood was higher than that in healthy children (26.26% ± 10.53% versus 15.2 ± 3.7%; P < 0.01), whereas the percentage of regulatory T cells (Tregs) was lower than that in healthy children (2.63% ± 0.94% versus 4.83% ± 1.42%; P < 0.001). After treatment, the percentage of CD20+ B cells decreased, and the percentage of Tregs significantly increased. The authors suggest CD20+ B cells and Tregs as potential markers for evaluating therapeutic efficacy and prognosis in these cases. [63]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!